CuraTeQ Biologics Announces Successful Phase 3 Trial for Xolair Biosimilar BP11
Hyderabad-based CuraTeQ Biologics, a wholly owned subsidiary of pharmaceutical giant Aurobindo Pharma, has reported highly positive top-line results from its Phase 3 clinical trial for BP11. This investigational biosimilar targets omalizumab, widely known by its brand name Xolair.
Trial Meets All Primary Endpoints with Strong Data
The comprehensive study successfully met all primary endpoints in patients diagnosed with chronic spontaneous urticaria who received the 300 mg dosage. The results demonstrated high comparability with the reference product, Xolair, establishing BP11 as a potentially significant therapeutic alternative.
The multinational trial enrolled 608 participants across approximately 80 clinical sites spanning seven European countries and India. This extensive geographical representation strengthens the validity and applicability of the findings across diverse patient populations.
Key Efficacy Measurements and Regulatory Pathway
The primary efficacy endpoint focused on the change from baseline in the 7-point Itch Severity Score at Week 12. This measurement is a critical requirement for regulatory submissions to both the United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
CuraTeQ confirmed that the results showed statistical equivalence, with confidence intervals comfortably falling within the predefined margin of -2.5 to 2.0. The company emphasized that these Phase 3 results, characterized by narrow confidence intervals, validate their clinical development strategy and execution quality.
"These Phase 3 results with narrow confidence intervals validate our clinical strategy and the team's execution in delivering a high-quality biosimilar. Detailed results will be submitted for regulatory review and presented at upcoming medical conferences," stated Dr. Arpitkumar Prajapati, Head of Clinical Development at CuraTeQ Biologics.Additional Endpoints and Future Regulatory Plans
The trial also included a co-primary endpoint assessing relative potency through a sophisticated 4-point assay. This endpoint successfully met its criteria, demonstrating clear parallelism between BP11 and the reference product Xolair across various dose levels. The findings indicated controlled variability, robust data integrity, and aligned efficacy profiles between the two treatments.
CuraTeQ plans to utilize these comprehensive results to support regulatory submissions for multiple indications, including:
- Chronic spontaneous urticaria
- Allergic asthma
- Chronic rhinosinusitis with nasal polyps
The company aims to submit these applications to both US and European drug regulatory authorities, marking a significant step toward global market access.
"BP11 demonstrates comparable efficacy and safety to Xolair, paving the way for patient access to affordable treatment options. We are planning to complete filing of BP11 with both EMA and FDA by the end of Q2 2026," explained Dr. Disha Dadke, Head of R&D and Regulatory Sciences at CuraTeQ Biologics.Strategic Implications for Patient Access and Treatment
The successful development of BP11 represents a strategic advancement in biosimilar therapeutics, potentially expanding treatment options for patients suffering from chronic immunological conditions. By demonstrating equivalence to the established reference product, CuraTeQ positions BP11 as a viable, potentially more accessible alternative in competitive pharmaceutical markets.
The company's commitment to completing regulatory filings by the second quarter of 2026 indicates a clear timeline for bringing this treatment to patients who could benefit from additional therapeutic choices in managing their chronic conditions.
